Metformin, a biguanide class antihyperglycemic agent widely prescribed for type 2 diabetes mellitus (T2DM), exerts its primary effect by activating AMP-activated protein kinase (AMPK) pathways, leading to reduced hepatic glucose production and enhanced insulin sensitivity [1,2,3,4]. Here, INS is linked to type 2 diabetes mellitus.